MicroGenDX is a leading molecular diagnostics laboratory specialising in next-generation sequencing (NGS) and quantitative polymerase chain reaction (qPCR) technology for microbial identification with a database of over 50,000 microbes to identify dominant bacteria and fungi.  The company focuses on providing advanced diagnostic solutions to healthcare providers across a wide range of medical fields, including urology, orthopaedics, ENT, wound care and infectious diseases. MicroGenDX is known for its expertise in identifying challenging infections with high accuracy, helping clinicians improve patient outcomes through timely and precise diagnostics.

Founded as PathoGenius in 2008 by Dr. Randy Wolcott, MicroGenDX pioneered the use of a 2-step process combining qPCR and NGS for microbial identification in 2010. In 2017, the laboratory was acquired by Rick Martin, head of commercialisation for this technology, and rebranded as MicroGenDX. Since then, the company has significantly expanded its reach, serving physicians across multiple specialties both nationally and internationally.

Today, MicroGenDX operates a state-of-the-art molecular diagnostics facility and has processed over 700,000 NGS tests. Equipped with advanced instrumentation, including Illumina MiSeq sequencers, the company offers comprehensive microbial diagnostics across fields such as urology, orthopaedics, ENT, podiatry, OB-GYN and more. Supported by a team of molecular biologists, bioinformaticians and clinicians, MicroGenDX is committed to improving clinical outcomes through innovative microbial identification.

Research Commitment

MicroGenDX is the only molecular lab that has published randomised outcome studies showing its test is superior to culture, as defined by relief of symptoms.The Science Behind MicroGenDX

College of America Pathologist (CAP)

Clinical Laboratory Improvement Amendments (CLIA)